Intellectual Property (IP), Artificial Intelligence (AI), Open Movements (OM)

Issues and developments related to IP, AI, and OM, examined in the IP and tech ethics graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology", coming in Summer 2025, includes major chapters on IP, AI, OM, and other emerging technologies (IoT, drones, robots, autonomous vehicles, VR/AR). Kip Currier, PhD, JD

Showing posts with label widening public access to generic meds. Show all posts

Thursday, March 31, 2016

GlaxoSmithKline to 'drop patents in poor countries for better drug access'; BBC News, 3/31/16

BBC News; GlaxoSmithKline to 'drop patents in poor countries for better drug access' :

"Pharmaceutical firm GlaxoSmithKline has said it wants to make it easier for manufacturers in the world's poorest countries to copy its medicines. The British company said it would not file patents in these countries.
Chief executive Sir Andrew Witty said he wanted to take a "graduated" approach to the company's "intellectual property" based on the wealth of nations around the globe.
Experts have described the plans as "brave and positive".
GSK hopes that by removing any fear of it filing for patent protection in poorer countries it will allow independent companies to make and sell versions of its drugs in those areas, thereby widening the public access to them."